Kenvue (NYSE:KVUE) Receives Hold (C-) Rating from Weiss Ratings

Key Points

• Kenvue's stock has been restated with a Hold (C-) rating by Weiss Ratings, reflecting a cautious outlook on the stock.
• Several investment analysts have adjusted their price targets, with UBS Group lowering it from $23.00 to $17.00 and setting a neutral rating.
• The company's latest quarterly earnings showed a decrease in revenue year-over-year, despite beating EPS estimates by a slight margin.

Kenvue (NYSE:KVUE - Get Free Report)'s stock had its "hold (c-)" rating restated by analysts at Weiss Ratings in a report released on Tuesday,Weiss Ratings reports.

Other analysts have also issued reports about the company. UBS Group reduced their target price on Kenvue from $23.00 to $17.00 and set a "neutral" rating on the stock in a report on Wednesday, October 8th. Canaccord Genuity Group reduced their target price on Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Rothschild & Co Redburn raised Kenvue from a "neutral" rating to a "buy" rating and reduced their target price for the stock from $22.50 to $22.00 in a report on Friday, September 26th. Rothschild Redb raised Kenvue from a "hold" rating to a "strong-buy" rating in a report on Friday, September 26th. Finally, Citigroup reduced their target price on Kenvue from $20.00 to $17.00 and set a "neutral" rating on the stock in a report on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $21.18.

Kenvue Stock Performance

NYSE KVUE traded down $0.08 on Tuesday, reaching $16.15. The stock had a trading volume of 8,076,022 shares, compared to its average volume of 20,398,809. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The firm has a fifty day moving average of $19.03 and a two-hundred day moving average of $21.25. Kenvue has a 1-year low of $15.47 and a 1-year high of $25.17. The company has a market cap of $30.98 billion, a P/E ratio of 21.82, a price-to-earnings-growth ratio of 2.39 and a beta of 0.72.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. During the same period in the prior year, the firm posted $0.32 EPS. The company's revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities research analysts anticipate that Kenvue will post 1.14 EPS for the current year.

Institutional Investors Weigh In On Kenvue

A number of hedge funds have recently added to or reduced their stakes in KVUE. Norges Bank bought a new stake in shares of Kenvue during the second quarter valued at approximately $537,418,000. Independent Franchise Partners LLP boosted its position in Kenvue by 233.4% in the second quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company's stock worth $654,388,000 after purchasing an additional 21,886,537 shares during the last quarter. Vanguard Group Inc. boosted its position in Kenvue by 4.9% in the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company's stock worth $5,494,882,000 after purchasing an additional 10,600,682 shares during the last quarter. Third Point LLC purchased a new position in shares of Kenvue during the 1st quarter valued at $213,422,000. Finally, Maverick Capital Ltd. purchased a new position in shares of Kenvue during the 1st quarter valued at $203,036,000. 97.64% of the stock is currently owned by institutional investors.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.